UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 3 | March 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 9 Issue 4
April-2022
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2204224


Registration ID:
400408

Page Number

c167-c176

Share This Article


Jetir RMS

Title

ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AND DEVELOPMENT AT EVERY PHASES

Abstract

The introduction of a new drug to the commercial market follows a complex and long process that typically spans over several years and entails large monetary costs due to high attrition rate. Because of this, there is a need to improve this process using updated technology such as artificial intelligence. Artificial intelligence used in various fields of drug discovery like discovery of new modifications, Preclinical Research, clinical development, FDA review, post marketing. And also, artificial intelligence can help test the adverse effects, side effects or toxicity of candidate drugs. Traditional drug discovery methods or target driven, which means that a known target is used to screen for small molecules that interact with it or affect its function in cells. However, due to complexity of cellular interactions and lack of knowledge of cellular pathways, these are minimal artificial intelligence in drug discovery market can overcome these obstacles. By detecting novel interactions and determining the functional significance of various cellular pathway components. Artificial intelligence has the potential to save more than 70 billion U.S. dollars in drug discovery costs by 2028. According to market research from Berkly. Artificial intelligence can speed up. Drug discovery by finding new insights into a disease, finding possible effects of a drug by testing molecular compounds, repurposing existing drugs, manipulating genetic material.

Key Words

KEYWORDS: -Artificial Intelligence, Neural networks, Drug Design, Drug Repurposing, De novo Design, Drug screening, Clinical Trails.

Cite This Article

"ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AND DEVELOPMENT AT EVERY PHASES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 4, page no.c167-c176, April-2022, Available :http://www.jetir.org/papers/JETIR2204224.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AND DEVELOPMENT AT EVERY PHASES", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 4, page no. ppc167-c176, April-2022, Available at : http://www.jetir.org/papers/JETIR2204224.pdf

Publication Details

Published Paper ID: JETIR2204224
Registration ID: 400408
Published In: Volume 9 | Issue 4 | Year April-2022
DOI (Digital Object Identifier):
Page No: c167-c176
Country: Banglore , Karnataka, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000281

Print This Page

Current Call For Paper

Jetir RMS